170 related articles for article (PubMed ID: 32171012)
1. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
Chan SY; Hughes RM; Woo K; Perales MA; Neofytos D; Papanicolaou G
Med Mycol; 2020 Nov; 58(8):1029-1036. PubMed ID: 32171012
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
[TBL] [Abstract][Full Text] [Related]
3. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
[TBL] [Abstract][Full Text] [Related]
4. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
5. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.
Amigues I; Cohen N; Chung D; Seo SK; Plescia C; Jakubowski A; Barker J; Papanicolaou GA
Biol Blood Marrow Transplant; 2010 Jan; 16(1):46-52. PubMed ID: 20053331
[TBL] [Abstract][Full Text] [Related]
6. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
Herity LB; Cruz OA; Aziz MT
J Oncol Pharm Pract; 2022 Jun; 28(4):794-804. PubMed ID: 33906508
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.
Cordonnier C; Rovira M; Maertens J; Olavarria E; Faucher C; Bilger K; Pigneux A; Cornely OA; Ullmann AJ; Bofarull RM; de la Cámara R; Weisser M; Liakopoulou E; Abecasis M; Heussel CP; Pineau M; Ljungman P; Einsele H; ;
Haematologica; 2010 Oct; 95(10):1762-8. PubMed ID: 20634495
[TBL] [Abstract][Full Text] [Related]
11. Why do lung transplant patients discontinue triazole prophylaxis?
Pennington KM; Razonable RR; Peters S; Scott JP; Wylam M; Daly RC; Kennedy CC
Transpl Infect Dis; 2019 Jun; 21(3):e13067. PubMed ID: 30866168
[TBL] [Abstract][Full Text] [Related]
12. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
[TBL] [Abstract][Full Text] [Related]
13. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
Marks DI; Liu Q; Slavin M
Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
[TBL] [Abstract][Full Text] [Related]
15. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
[TBL] [Abstract][Full Text] [Related]
16. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
17. Association between drug tolerability and medical resource use in prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplant.
Gao X; Marks DI; Schlamm HT; Ji X; Stephens JM; Tarallo M
J Med Econ; 2013 Aug; 16(8):1061-70. PubMed ID: 23730943
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant.
Dvorak CC; Fisher BT; Esbenshade AJ; Nieder ML; Alexander S; Steinbach WJ; Dang H; Villaluna D; Chen L; Skeens M; Zaoutis TE; Sung L
J Pediatric Infect Dis Soc; 2021 Apr; 10(4):417-425. PubMed ID: 33136159
[TBL] [Abstract][Full Text] [Related]
19. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
[TBL] [Abstract][Full Text] [Related]
20. Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.
Akahoshi Y; Kimura SI; Gomyo A; Hayakawa J; Tamaki M; Harada N; Kusuda M; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Nakasone H; Kako S; Kanda Y
Infect Dis (Lond); 2018 Apr; 50(4):280-288. PubMed ID: 29087731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]